Raymond James Financial Services Advisors’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-14,630	Closed	-$9K	–	2923
2018 Q4	$9K	Sell	14,630 -3,308	-18%	-$3.43K	﹤0.01%	2546
2018 Q3	$23K	Sell	17,938 -1,518	-8%	-$2.36K	﹤0.01%	2759
2018 Q2	$26K	Buy	19,456 +2,417	+14%	+$3.7K	﹤0.01%	2713
2018 Q1	$25K	Buy	17,039 +5,091	+43%	+$10.6K	﹤0.01%	2485
2017 Q4	$27K	Buy	11,948 +1,274	+12%	+$3.22K	﹤0.01%	2473
2017 Q3	$36K	Buy	+10,674	New	+$35.9K	﹤0.01%	2478

Raymond James Financial Services Advisors's AST Position: Q1 2019 in Review

Raymond James Financial Services Advisors sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 14,630 shares — an estimated $9K sold.

Raymond James Financial Services Advisors first reported a position in AST in Q3 2017 and held it in 6 quarters. The position peaked at $36K in Q3 2017. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.

Raymond James Financial Services Advisors reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
Raymond James Financial Services Advisors sold 14,630 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $9K.
Raymond James Financial Services Advisors first reported a position in Asterias Biotherapeutics Inc. Series A in Q3 2017 and held it in 6 quarters.
Raymond James Financial Services Advisors's Asterias Biotherapeutics Inc. Series A position peaked at $36K in Q3 2017.
0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2019, filed 6 May 2019.